PriceTargets.com logo

Chemomab Therapeutics - CMMB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 504.98%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.41 As of 05/21/2025 12:18 PM ET
▲ +0.015 (1.08%)

This chart shows the closing price for CMMB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Chemomab Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMMB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMMB

Analyst Price Target is $8.50
▲ +504.98% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Chemomab Therapeutics in the last 3 months. The average price target is $8.50, with a high forecast of $10.00 and a low forecast of $7.00. The average price target represents a 504.98% upside from the last price of $1.41.

This chart shows the closing price for CMMB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Chemomab Therapeutics. This rating has held steady since January 2025, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/26/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/16/2025OppenheimerLower TargetOutperform ➝ Outperform$11.00 ➝ $10.00
2/20/2025Maxim GroupBoost TargetBuy ➝ Buy$4.00 ➝ $7.00
11/15/2024OppenheimerReiterated RatingOutperform ➝ Outperform$13.00 ➝ $11.00
5/24/2024Maxim GroupUpgradeStrong-Buy
5/13/2024Maxim GroupInitiated CoverageBuy$4.00
5/6/2024OppenheimerUpgradeMarket Perform ➝ Outperform$6.00
12/19/2023Roth CapitalReiterated RatingBuy
12/19/2023Roth MkmReiterated RatingBuy$7.00
10/6/2023Roth CapitalReiterated RatingBuy
10/6/2023Roth MkmInitiated CoverageBuy$7.00
6/7/2023OppenheimerDowngradeOutperform ➝ Market Perform
4/18/2023OppenheimerLower Target$12.00 ➝ $7.00
3/10/2022OppenheimerLower TargetOutperform$30.00 ➝ $20.00
12/7/2021AegisInitiated CoverageBuy$30.00
7/2/2021OppenheimerInitiated CoverageBuy$42.00
5/26/2021Cantor FitzgeraldInitiated CoverageOverweight$45.00
5/24/2021OppenheimerReiterated RatingBuy$42.00
5/7/2021OppenheimerInitiated CoverageOutperform$42.00
(Data available from 5/21/2020 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2025
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2025

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Chemomab Therapeutics logo
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Read More

Today's Range

Now: $1.41
Low: $1.38
High: $1.42

50 Day Range

MA: $1.21
Low: $0.94
High: $1.50

52 Week Range

Now: $1.41
Low: $0.78
High: $2.55

Volume

20,768 shs

Average Volume

209,523 shs

Market Capitalization

$20.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Chemomab Therapeutics?

The following equities research analysts have issued research reports on Chemomab Therapeutics in the last year: Maxim Group, and Oppenheimer Holdings Inc..
View the latest analyst ratings for CMMB.

What is the current price target for Chemomab Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Chemomab Therapeutics in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 505.0%. Oppenheimer Holdings Inc. has the highest price target set, predicting CMMB will reach $10.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $7.00 for Chemomab Therapeutics in the next year.
View the latest price targets for CMMB.

What is the current consensus analyst rating for Chemomab Therapeutics?

Chemomab Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CMMB will outperform the market and that investors should add to their positions of Chemomab Therapeutics.
View the latest ratings for CMMB.

What other companies compete with Chemomab Therapeutics?

Other companies that are similar to Chemomab Therapeutics include CervoMed, Pyxis Oncology, Telomir Pharmaceuticals, ESSA Pharma and Jasper Therapeutics. Learn More about companies similar to Chemomab Therapeutics.

How do I contact Chemomab Therapeutics' investor relations team?

Chemomab Therapeutics' physical mailing address is KIRYAT ATIDIM BUILDING 7, TEL AVIV L3, 6158002. The company's listed phone number is 972-77-331-0156 and its investor relations email address is [email protected]. The official website for Chemomab Therapeutics is www.chemomab.com. Learn More about contacing Chemomab Therapeutics investor relations.